Morgan Stanley Global Blood Therapeutics, Inc. Transaction History

Morgan Stanley

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$32.4 - $68.18 $12.7 Million - $26.7 Million	-391,669 Reduced 45.74%	464,630 $31.6 Million
Q2 2022 Oct 27, 2022	BUY	$22.3 - $37.39 $6.42 Million - $10.8 Million	287,760 Added 50.61%	856,299 $27.4 Million
Q2 2022 Aug 15, 2022	BUY	$22.3 - $37.39 $6.42 Million - $10.8 Million	287,760 Added 50.61%	856,299 $27.4 Million
Q1 2022 Oct 27, 2022	SELL	$25.68 - $35.59 $7.39 Million - $10.2 Million	-287,760 Reduced 33.61%	568,539 $19.7 Million
Q1 2022 May 13, 2022	BUY	$25.68 - $35.59 $9.44 Million - $13.1 Million	367,681 Added 183.06%	568,539 $19.7 Million
Q4 2021 Feb 14, 2022	SELL	$24.9 - $40.26 $2.75 Million - $4.44 Million	-110,385 Reduced 35.47%	200,858 $5.88 Million
Q3 2021 Nov 15, 2021	BUY	$25.48 - $37.34 $7.93 Million - $11.6 Million	311,243 New	311,243 $7.93 Million

288K

Ticker GBT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,476,200
Market Cap $4.62B
Description
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.